Want to see ZNTL full AI Analyst Report?

Zentalis Pharmaceuticals (ZNTL) Price & Analysis

396 Followers

ZNTL Stock Chart & Stats

$1.41

-$0.17(-5.69%)

At close: Jan 08 4:00 PM EST

$1.41

-$0.17(-5.69%)

Day’s Range― - ―

52-Week Range$1.21 - $6.95

Previous CloseN/A

Volume750.15K

Average Volume (3M)716.92K

Market Cap

$325.32M

Enterprise Value-$8.69

Total Cash (Recent Filing)$211.76M

Total Debt (Recent Filing)$38.65M

Price to Earnings (P/E)―

Beta3.47

Next Earnings

Aug 12, 2026

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.73

Shares Outstanding71,186,350

10 Day Avg. Volume819,524

30 Day Avg. Volume716,917

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.45

Price to Sales (P/S)0.00

P/FCF Ratio-0.77

Enterprise Value/Market Cap>-0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price Target

$6.67

Price Target Upside372.81% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-1.88

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Pipeline ProgressAdvancing azenosertib into a randomized Phase 3 (ASPENOVA) aligned with FDA expectations materially de-risks the program if successful. A positive confirmatory readout would transition Zentalis from development-stage to potential commercialization, changing long-term revenue and strategic optionality.

Encouraging Clinical Combo DataRobust response rates and tolerability in heavily pretreated, platinum-resistant ovarian cancer suggest the drug can be effective in real-world combination regimens. Durable efficacy with manageable safety supports broader label and commercial combinations, expanding addressable market beyond monotherapy.

Cash Runway And Modest LeverageA >$200M cash balance and modest debt relative to equity provide a multi-quarter runway to complete pivotal studies and regulatory activities. This capital buffer reduces immediate refinancing pressure versus peers, allowing management to fund trials and strategic execution toward value-driving milestones.

Bears Say

No Revenue; Persistent BurnZero recurring revenue and substantial negative operating and free cash flow mean the company depends on external financing to sustain operations. Persistent burn increases dilution risk and constrains strategic flexibility if trial timelines slip or fundraising conditions worsen, impacting long-term stability.

Eroding Equity And Negative ReturnsMaterial declines in equity and assets alongside a negative ROE reflect that cumulative losses are consuming the balance sheet. This erosion reduces the company's financial cushion against setbacks and may worsen borrowing terms or accelerate dilution if further capital is required.

Concentrated Clinical/regulatory RiskThe company's fate is tightly linked to azenosertib's pivotal outcomes and companion diagnostic validation. Failure, delay, or unfavorable readouts in ASPENOVA or DENALI would significantly impair commercialization prospects and long-term viability, a structural risk for single-lead program biotechs.

Zentalis Pharmaceuticals News

Zentalis initiated with an Outperform at Mizuho

Mizuho analyst Graig Suvannavejh initiated coverage of Zentalis (ZNTL) with an Outperform rating and $8 price target The...

1d ago

ZNTL

Zentalis Shareholders Back Directors, Auditors and Executive Pay

Zentalis Pharmaceuticals ( ($ZNTL) ) has shared an update. On June 16, 2026, Zentalis Pharmaceuticals, Inc. held its...

30d ago

ZNTL

Zentalis assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Zentalis (ZNTL) with an Outperform rating and $9 price target The company is entering...

1M ago

ZNTL

Zentalis Pharmaceuticals Expands Board, Appoints New Director

The latest update is out from Zentalis Pharmaceuticals ( ($ZNTL) ). Effective May 22, 2026, Zentalis Pharmaceuticals expanded...

2M ago

ZNTL

Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals,...

2M ago

ZNTL

Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer

Zentalis Pharmaceuticals ( ($ZNTL) ) has issued an announcement. On May 21, 2026, Zentalis Pharmaceuticals reported Phase 1b...

2M ago

ZNTL

Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts

Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals and keeping the price...

2M ago

ZNTL

Zentalis reports Q1 EPS (50c), consensus (52c)

“This quarter, we built momentum with achievement of key milestones advancing azenosertib in our registration-intended Phase 2 and...

2M ago

ZNTL

Zentalis Advances Azenosertib with New Trial Updates

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an announcement. On May 12, 2026, Zentalis Pharmaceuticals reported first-quarter 2026...

2M ago

ZNTL

ZNTL Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Zentalis Pharmaceuticals Inc (ZNTL) is scheduled to report 1st quarter earnings on 05/13/2026. Regarding Q1 estimates, Wall Street...

2M ago

ZNTL

Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On May 5, 2026, Zentalis Pharmaceuticals announced that the...

2M ago

ZNTL

Zentalis Highlights New Azenosertib Data in Breast Cancer

Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On April 17, 2026, at the American Association for...

3M ago

ZNTL

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Zentalis (ZNTL) announced data from two posters being presented at the 2026 American Association for Cancer Research Annual...

3M ago

ZNTL

Midday Fly By: CoreWeave inks Anthropic, TSMC reports March sales bump

The major averages were mixed near noon, with the Dow Jones Industrial Average in the red, the Nasdaq...

3M ago

ZNTL FAQ

What was Zentalis Pharmaceuticals’s price range in the past 12 months?

Zentalis Pharmaceuticals lowest stock price was $1.21 and its highest was $6.95 in the past 12 months.

What is Zentalis Pharmaceuticals’s market cap?

Zentalis Pharmaceuticals’s market cap is $325.32M.

When is Zentalis Pharmaceuticals’s upcoming earnings report date?

Zentalis Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 25 days.

How were Zentalis Pharmaceuticals’s earnings last quarter?

Zentalis Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.023.

Is Zentalis Pharmaceuticals overvalued?

According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zentalis Pharmaceuticals pay dividends?

Zentalis Pharmaceuticals does not currently pay dividends.

What is Zentalis Pharmaceuticals’s EPS estimate?

Zentalis Pharmaceuticals’s EPS estimate is -0.49.

How many shares outstanding does Zentalis Pharmaceuticals have?

Zentalis Pharmaceuticals has 71,186,350 shares outstanding.

What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?

Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?

Currently, no hedge funds are holding shares in ZNTL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zentalis Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.61%

Trailing 12-Months

Asset Growth

-34.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals (ZNTL) Earnings & Revenues

Historic Earnings Reports

ZNTL Stock 12 Month Forecast

Average Price Target

$6.67

▲(372.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.666666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.355,4.78923076923077,5.223461538461539,5.657692307692308,6.091923076923077,6.526153846153846,6.960384615384616,7.394615384615385,7.828846153846154,8.263076923076923,8.697307692307692,9.131538461538462,9.56576923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.355,4.532820512820513,4.710641025641026,4.888461538461539,5.066282051282052,5.2441025641025645,5.421923076923077,5.59974358974359,5.777564102564103,5.955384615384616,6.1332051282051285,6.311025641025641,6.488846153846154,{"y":6.666666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.355,4.327692307692308,4.3003846153846155,4.273076923076923,4.245769230769231,4.218461538461539,4.1911538461538465,4.163846153846154,4.1365384615384615,4.109230769230769,4.081923076923077,4.054615384615385,4.0273076923076925,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.54,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.355,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >